Squidoo

By Editorial Team -

Comments

Post a Comment

Pages

Popular posts from this blog

AI Wearable Technology Innovations 2025–2026: Health, Fitness & Beyond

By -
Image
Artificial intelligence (AI) is redefining what wearable technology can do. In 2025 and heading into 2026, wearables are no longer passive tracking devices — they are becoming intelligent, predictive, and deeply personalized health and lifestyle companions. Source:  Grand View Research From smart rings and AI fitness coaches to augmented reality glasses and skin-integrated sensors, AI-powered wearables are transforming healthcare, wellness, productivity, and human-machine interaction. 1. AI-Driven Health Monitoring and Early Detection Advanced AI algorithms are dramatically improving the accuracy of wearable health sensors. Machine learning models filter noise, personalize baselines, and detect anomalies related to heart rhythm, blood oxygen, stress, and sleep. Modern wearables now approach clinical-grade monitoring, enabling early detection of conditions such as arrhythmias, sleep disorders, and metabolic stress — a major step toward preventive healthcare. Best AI Smart Ring: ...
Read more

Largest Pharma Companies in the World (2025–2026 Revenue Rankings)

By -
Image
Table of Contents: Largest Pharma Companies by Revenue (Global Ranking) Top 10 Pharmaceutical Companies by Market Cap in 2025 Top 10 Most Anticipated Drug Launches of 2025 Top 10 Drugs Losing US Exclusivity in 2025 The largest pharma companies in the world play a central role in global healthcare, developing blockbuster drugs for cancer, cardiovascular disease, immunology, vaccines, and metabolic disorders. In 2025, the biggest pharmaceutical companies by revenue continued to dominate through scale, research spending, and global distribution—despite growing pressure from patent expirations, biosimilars, and pricing reforms. Medical stocks are releasing earnings reports in droves. Eli Lilly and Co (LLY.US) targets $80 billion in 2026 revenue with standout performance; Novo-Nordisk A/S (NVO.US) beats Q4 expectations but lowers 2026 guidance due to pricing pressures. The largest pharma companies are defined not only by revenue, but by global scale, research investment, and thera...
Read more

Bitcoin Nasdaq Correlation: The Correlation between the Nasdaq index and Cryptocurrencies (March 2026 Version)

By -
Image
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Updated Analysis as of March 2026 Fast-forward to March 9, 2026, and the correlation has flipped dramatically positive amid renewed volatility. The 30-day correlation coefficient between Bitcoin and the S&P 500 (closely tied to Nasdaq trends) stands at 0.74, the highest level this year. Similarly, Bitcoin's correlation with the Nasdaq has swung from -0.68 in early February to +0.72, highlighting sensitivity to risk-off flows and macro events like geopolitical tensions. Bitcoin remains strongly aligned with the Nasdaq 100, showing little correlation with gold or bonds, reinforcing its role as a risk asset rather than a safe haven. Current Bitcoin price hovers around $65,978–$66,000, consolidating in a $60,000–$72,000 range after a 22% decline from last year...
Read more

AI Demand Drives Ongoing SSD & Memory Shortages: Prices Surging Further into 2026 and Beyond

By -
Image
As we enter 2026, the memory and storage crunch predicted in late 2025 has materialized with even greater intensity. AI data centers continue to dominate global production of DRAM and NAND flash, pushing prices sharply higher and extending lead times across consumer, PC, and enterprise segments. Nearly every analyst firm and memory maker is now warning of looming NAND and DRAM shortages that will send SSD and memory prices skyrocketing over the coming months and years, with some even predicting a shortage that will last a decade. For the better part of two years, storage upgrades have been a rare bright spot for PC builders. SSD prices cratered to all-time lows in 2023 , with high-performance NVMe drives selling for little more than the cost of a modest mechanical hard disk. DRAM followed a similar trajectory, dropping to price points not seen in nearly a decade. In 2024, the pendulum swung firmly in the other direction, with prices for both NAND flash and DRAM sta...
Read more

Top 10 Food Companies by Revenue — 2026 Update

By -
Image
The ten largest food and beverage companies in the world remain Nestle, Ahold Delhaize, PepsiCo., Archer Daniels Midland, Sysco, JBS, Performance Food Group, Anheuser-Busch InBev, Unilever, and Tyson Foods. The global food and beverage industry remains one of the largest and most resilient sectors of the world economy, generating trillions of dollars in annual revenue . While consumer preferences, inflation, and supply-chain realignments continue to reshape the market, a relatively small group of multinational corporations still dominate global food sales. This January 2026 update revises our original 2025 rankings using the latest available full-year 2024 results, 2025 trailing-twelve-month (TTM) data, and confirmed late-2025 corporate developments , including major mergers, recalls, and strategic restructurings.  Top 10 Food Companies by Revenue This ranking reflects the largest companies primarily by annual revenue, emphasizing food production, processing, distri...
Read more

NVIDIA vs AMD GPUs for AI: 2026 Comparison and Recommendations

By -
Image
In the rapidly evolving world of AI in 2026, choosing between NVIDIA and AMD GPUs boils down to ecosystem maturity, performance needs, and budget.  NVIDIA GPUs generally lead in AI performance, particularly for short- to medium-term rentals, due to their larger market presence and competitive pricing. However, AMD has been enhancing its offerings and can outperform NVIDIA in certain workloads, so the best choice depends on the specific use case. NVIDIA's dominance stems from its CUDA platform, which powers over 90% of AI frameworks, while AMD is gaining ground with ROCm's open-source approach and cost-effective hardware. AMD's Instinct MI300X and upcoming MI350 series offer competitive inference speeds, sometimes at 40% better efficiency than NVIDIA's Blackwell. This article compares their architectures, benchmarks for AI tasks like training and inference, and provides tailored recommendations with Amazon links for accessible models. Key Differences Between NVIDIA and ...
Read more

Did Steve Jobs Refuse Treatment for Pancreatic Cancer?

By Editorial Team -
Image
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Read more

Top 10 Drugs by Worldwide Sales in 2025

By -
Image
The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025. Summary 1. Keytruda (Merck): 31B 2. Ozempic (Novo Nordisk): 21 B 3. Mounjaro (ELi Lilly): 19 B 4. Dupixent (Sanofi and Regeneron): 17 B 5. Wegovy (Novo Nordisk): 14 B 6. Biktarvy (Gilead Sciences): 13.4 B 7. Skyrizi (Abbvie): 13 B 8. Eliquis (Bristol-Myers Squibb): 13 B 9. Darzalex (Johnson & Johnson): 13 B 10. Humira (Abbvie): 12.5 B Highlights and Market Trends Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year...
Read more

9 Best Crypto Scam Recovery Companies (2026 Guide): What Actually Works

By -
Image
Introduction Crypto scams have become more sophisticated in 2026, driven by AI-powered phishing, fake recovery agents, deepfake influencers, and cross-chain laundering. While blockchain transparency makes tracing possible, crypto transactions remain irreversible , and recovery is never guaranteed. This updated 2026 guide explains: Which crypto scam recovery services are legitimate What recovery companies can and cannot do How to avoid recovery scams , now more common than ever When law enforcement and exchanges matter more than private firms Critical warning: Any service promising guaranteed recovery in 2026 is likely to be a scam as well. What Legitimate Crypto Recovery Services Can Do (2026 Reality Check) They CAN: Trace stolen funds on public blockchains Identify laundering paths (bridges, mixers, exchanges) Produce forensic reports for exchanges, lawyers, or police Assist with exchange...
Read more

Novo Nordisk vs. Eli Lilly — The GLP‑1 Market Showdown (2026 Perspective)

By -
Image
The fight for dominance in GLP‑1 medicines  — drugs that boost weight loss and control diabetes — has reshaped the pharmaceutical landscape. As of early 2026, two companies lead the sector:  Novo Nordisk  and  Eli Lilly . Together they compete in a market projected to exceed  $100 billion by 2030 , with obesity therapies driving most of the value. ( onedayadvisor.com ) 1. Market Context & Recent Headlines (Feb 2026) Novo Nordisk’s setback: Experimental obesity therapy CagriSema underperformed against Lilly’s tirzepatide in a Phase 3 trial, causing a share price drop. ( reuters.com ) Heart‑health advantage for Wegovy: Real-world data suggest Wegovy users may have lower heart-attack risk compared to tirzepatide patients. ( reuters.com ) Alzheimer’s trial failure: Novo’s GLP‑1 candidate failed in two Alzheimer’s trials, highlighting limits outside metabolic disease. ( axios.com ) Cost pressures: Novo announced ~9,000 job cuts due to competition and slowin...
Read more